Michael S. Brown Sells 1,535 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Michael S. Brown sold 1,535 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $1,040.00, for a total value of $1,596,400.00. Following the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,437,280. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Regeneron Pharmaceuticals Trading Down 0.6 %

NASDAQ:REGN opened at $1,039.11 on Wednesday. The firm has a market cap of $114.50 billion, a P/E ratio of 30.70, a PEG ratio of 2.14 and a beta of 0.13. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The stock’s 50 day simple moving average is $960.33 and its 200-day simple moving average is $939.67. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $1,052.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The business had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Truist Financial restated a “buy” rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Cantor Fitzgerald restated a “neutral” rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. Morgan Stanley boosted their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 13th. TD Cowen boosted their target price on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, Evercore ISI started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $998.09.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. West Paces Advisors Inc. grew its holdings in Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares during the period. Crewe Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter worth $28,000. Fortitude Family Office LLC acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $31,000. MCF Advisors LLC boosted its position in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 12 shares in the last quarter. Finally, Criterion Capital Advisors LLC purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter worth $37,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.